1. Home
  2. HYFT vs IMA Comparison

HYFT vs IMA Comparison

Compare HYFT & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MindWalk Holdings Corp.

HYFT

MindWalk Holdings Corp.

N/A

Current Price

$0.98

Market Cap

56.5M

Sector

Health Care

ML Signal

N/A

IMA

ImageneBio Inc.

N/A

Current Price

$3.65

Market Cap

66.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HYFT
IMA
Founded
1983
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.5M
66.3M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
HYFT
IMA
Price
$0.98
$3.65
Analyst Decision
Strong Buy
Buy
Analyst Count
3
4
Target Price
$4.33
★ $18.00
AVG Volume (30 Days)
★ 224.2K
10.2K
Earning Date
12-14-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $800,000.00
Revenue This Year
$12.86
N/A
Revenue Next Year
$22.94
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.96
$3.44
52 Week High
$3.00
$8.25

Technical Indicators

Market Signals
Indicator
HYFT
IMA
Relative Strength Index (RSI) 36.19 23.89
Support Level N/A N/A
Resistance Level $1.50 $6.13
Average True Range (ATR) 0.09 0.24
MACD -0.01 -0.04
Stochastic Oscillator 30.35 5.55

Price Performance

Historical Comparison
HYFT
IMA

About HYFT MindWalk Holdings Corp.

MindWalk Holdings Corp is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.

About IMA ImageneBio Inc.

ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.

Share on Social Networks: